Sectors & Industries HealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2023)
Top general drug manufacturer stocks in 2023 ranked by overall Zen Score. See the best general drug manufacturer stocks to buy now, according to analyst forecasts for the drug manufacturers - general industry.

Industry: Drug Manufacturers - Gene...

Zen Score Price Valuation Financials Forecast Earnings & Revenue Dividends Ownership Technicals

Ticker	Company	Exchange	Industry	Market Cap	Price	1d %	EBITDA	P/E	D/E
MRK	MERCK & CO INC	NYSE	Drug Manufacturers - General	$266.04B	$104.80	0.55%	$20.35B	18.29x	1.37
PFE	PFIZER INC	NYSE	Drug Manufacturers - General	$226.95B	$40.39	0.52%	$39.76B	7.23x	1.06
JNJ	JOHNSON & JOHNSON	NYSE	Drug Manufacturers - General	$397.54B	$152.65	1.01%	$28.97B	22.35x	1.44
GSK	GSK PLC	NYSE	Drug Manufacturers - General	$69.21B	$34.38	-2.39%	$19.93B	3.84x	4.72
AMGN	AMGEN INC	NASDAQ	Drug Manufacturers - General	$127.10B	$238.03	2.11%	$12.17B	19.54x	16.79
BIIB	BIOGEN INC	NASDAQ	Drug Manufacturers - General	$39.02B	$270.03	1.83%	$4.32B	12.88x	0.83
BMY	BRISTOL MYERS SQUIBB CO	NYSE	Drug Manufacturers - General	$142.05B	$67.68	1.05%	$17.97B	22.79x	2.12
SNY	SANOFI	NASDAQ	Drug Manufacturers - General	$132.67B	$52.61	1.70%	$15.31B	14.63x	0.69
GILD	GILEAD SCIENCES INC	NASDAQ	Drug Manufacturers - General	$99.77B	$80.00	1.57%	$8.88B	21.86x	1.98
ABBV	ABBVIE INC	NYSE	Drug Manufacturers - General	$279.60B	$158.02	1.75%	$23.98B	23.76x	7.04
HZNP	HORIZON THERAPEUTICS PUBLIC LTD CO	NASDAQ	Drug Manufacturers - General	$24.79B	$108.52	0.67%	$1.00B	47.60x	0.80
LLY	ELI LILLY & CO	NYSE	Drug Manufacturers - General	$319.42B	$336.13	1.05%	$8.33B	48.50x	3.64
NVS	NOVARTIS AG	NYSE	Drug Manufacturers - General	$177.18B	$83.59	1.31%	$20.75B	26.20x	0.98
AZN	ASTRAZENECA PLC	NASDAQ	Drug Manufacturers - General	$210.49B	$67.91	0.97%	$9.32B	64.07x	1.60
TSVT	2SEVENTY BIO INC	NASDAQ	Drug Manufacturers - General	$463.75M	$9.24	-2.63%	-$242.62M	-1.30x	1.12
GRFS	GRIFOLS SA	NASDAQ	Drug Manufacturers - General	$4.71B	$6.85	-1.15%	$990.88M	22.53x	2.16
OGN	ORGANON & CO	NYSE	Drug Manufacturers - General	$5.56B	$21.86	2.05%	$1.76B	6.06x	-13.28

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Mar 2023?

According to Zen Score, the 3 best general drug manufacturer stocks to buy right now are:

1. Merck & Co (NYSE:MRK)

Merck & Co (NYSE:MRK) is the top general drug manufacturer stock with a Zen Score of 63, which is 26 points higher than the general drug manufacturer industry average of 37. It passed 24 out of 38 due diligence checks and has strong fundamentals. Merck & Co has seen its stock return 30.33% over the past year, overperforming other general drug manufacturer stocks by 27 percentage points.

Merck & Co has an average 1 year price target of $121.38, an upside of 15.82% from Merck & Co's current stock price of $104.80.

Merck & Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 16 analysts covering Merck & Co, 62.5% have issued a Strong Buy rating, 25% have issued a Buy, 12.5% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) is the second best general drug manufacturer stock with a Zen Score of 55, which is 18 points higher than the general drug manufacturer industry average of 37. It passed 20 out of 38 due diligence checks and has strong fundamentals. Pfizer has seen its stock lose -23.2% over the past year, underperforming other general drug manufacturer stocks by -27 percentage points.

Pfizer has an average 1 year price target of $51.23, an upside of 26.84% from Pfizer's current stock price of $40.39.

Pfizer stock has a consensus Buy recommendation according to Wall Street analysts. Of the 13 analysts covering Pfizer, 15.38% have issued a Strong Buy rating, 23.08% have issued a Buy, 61.54% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) is the third best general drug manufacturer stock with a Zen Score of 49, which is 12 points higher than the general drug manufacturer industry average of 37. It passed 18 out of 38 due diligence checks and has strong fundamentals. Johnson & Johnson has seen its stock lose -12.89% over the past year, underperforming other general drug manufacturer stocks by -16 percentage points.

Johnson & Johnson has an average 1 year price target of $182.78, an upside of 19.74% from Johnson & Johnson's current stock price of $152.65.

Johnson & Johnson stock has a consensus Buy recommendation according to Wall Street analysts. Of the 9 analysts covering Johnson & Johnson, 22.22% have issued a Strong Buy rating, 22.22% have issued a Buy, 55.56% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the general drug manufacturer stocks with highest dividends?

Out of 12 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Gsk (NYSE:GSK)

Gsk (NYSE:GSK) has an annual dividend yield of 4.32%, which is 1 percentage points higher than the general drug manufacturer industry average of 3.18%. Gsk's dividend payout is not stable, having dropped more than 10% ten times in the last 10 years. Gsk's dividend has not shown consistent growth over the last 10 years.

Gsk's dividend payout ratio of 16.6% indicates that its dividend yield is sustainable for the long-term.

2. Novartis Ag (NYSE:NVS)

Novartis Ag (NYSE:NVS) has an annual dividend yield of 4.15%, which is 1 percentage points higher than the general drug manufacturer industry average of 3.18%. Novartis Ag's dividend payout is not stable, having dropped more than 10% three times in the last 10 years. Novartis Ag's dividend has shown consistent growth over the last 10 years.

Novartis Ag's dividend payout ratio of 105.2% indicates that its dividend yield might not be sustainable for the long-term.

3. Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) has an annual dividend yield of 3.99%, which is 1 percentage points higher than the general drug manufacturer industry average of 3.18%. Pfizer's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Pfizer's dividend has shown consistent growth over the last 10 years.

Pfizer's dividend payout ratio of 28.8% indicates that its dividend yield is sustainable for the long-term.

Why are general drug manufacturer stocks up?

General drug manufacturer stocks were up 1.26% in the last day, and up 2.17% over the last week.

We couldn't find a catalyst for why general drug manufacturer stocks are up.

What are the most undervalued general drug manufacturer stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued general drug manufacturer stocks right now are:

1. Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) is the most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Biogen has a valuation score of 57, which is 23 points higher than the general drug manufacturer industry average of 34. It passed 4 out of 7 valuation due diligence checks.

Biogen's stock has gained 26.77% in the past year. It has overperformed other stocks in the general drug manufacturer industry by 23 percentage points.

2. Gsk (NYSE:GSK)

Gsk (NYSE:GSK) is the second most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Gsk has a valuation score of 57, which is 23 points higher than the general drug manufacturer industry average of 34. It passed 4 out of 7 valuation due diligence checks.

Gsk's stock has dropped -36.48% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -40 percentage points.

3. Sanofi (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) is the third most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Sanofi has a valuation score of 57, which is 23 points higher than the general drug manufacturer industry average of 34. It passed 4 out of 7 valuation due diligence checks.

Sanofi's stock has gained 2.77% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -1 percentage points.

Are general drug manufacturer stocks a good buy now?

61.54% of general drug manufacturer stocks rated by analysts are a buy right now. On average, analysts expect general drug manufacturer stocks to rise by 14.35% over the next year.

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 26.79x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.